Effectiveness and Tolerability of Switching to Aripiprazole Once Monthly from Antipsychotic Polypharmacy and/or Other Long Acting Injectable Antipsychotics for Patients with Schizophrenia in Routine Practice: A Retrospective, Observation Study
2
조회
0
다운로드
5
인용
0
참고문헌
키워드
초록
Objective: This study was done for collection of real world data of Aripiprazole Once Monthly (AOM) in patients with schizophrenia. Methods: The observation was up to 12 months from the first use of AOM in patients with antipsychotic polypharmacy (APpoly)/other long acting injectable antipsychotics (LAIs) for treatment of schizophrenia in daily practice. Demographics and available clinical information such as The Positive and Negative Syndrome Scale (PANSS) and Clinical Global Impression-severity (CGI-S) scores were retrieved from the electronic medical record (EMR). Adverse events were also noted as described in EMR. Results: Eighteen patients were found to be switched from APpoly/LAIs. Mean numbers of previous APs treatment failure and immediate prior APs were 2.2 and 2.4, respectively; most commonly used APs before AOM were aripiprazole, blonanserin, quetiapine, and risperidone. Mean number of combined APs before AOM significantly decreased from 2.4 use to 0.7 at month 12 (p ＜ 0.0001). The PANSS total (71.7 to 62.1, p = 0.000) and CGI-S (3.4 to 3.1, p = 0.008) scores were also significantly decreased from baseline (first use of AOM) to month 12, respectively. Other various psychotropics including anxiolytics were also significantly and substantially decreased at some point from baseline throughout the observation period as well. Mild hand tremor and akathisia were developed in 3 patients. Conclusion: The present observation study clearly confirmed the use of AOM should be also effective and tolerable treatment option for patients with APpoly/LAIs in the real world practice. Subsequent, adequately-powered, and well-controlled clinical trials are warranted in near future.
Abstract
Objective: This study was done for collection of real world data of Aripiprazole Once Monthly (AOM) in patients with schizophrenia. Methods: The observation was up to 12 months from the first use of AOM in patients with antipsychotic polypharmacy (APpoly)/other long acting injectable antipsychotics (LAIs) for treatment of schizophrenia in daily practice. Demographics and available clinical information such as The Positive and Negative Syndrome Scale (PANSS) and Clinical Global Impression-severity (CGI-S) scores were retrieved from the electronic medical record (EMR). Adverse events were also noted as described in EMR. Results: Eighteen patients were found to be switched from APpoly/LAIs. Mean numbers of previous APs treatment failure and immediate prior APs were 2.2 and 2.4, respectively; most commonly used APs before AOM were aripiprazole, blonanserin, quetiapine, and risperidone. Mean number of combined APs before AOM significantly decreased from 2.4 use to 0.7 at month 12 (p ＜ 0.0001). The PANSS total (71.7 to 62.1, p = 0.000) and CGI-S (3.4 to 3.1, p = 0.008) scores were also significantly decreased from baseline (first use of AOM) to month 12, respectively. Other various psychotropics including anxiolytics were also significantly and substantially decreased at some point from baseline throughout the observation period as well. Mild hand tremor and akathisia were developed in 3 patients. Conclusion: The present observation study clearly confirmed the use of AOM should be also effective and tolerable treatment option for patients with APpoly/LAIs in the real world practice. Subsequent, adequately-powered, and well-controlled clinical trials are warranted in near future.
참고문헌 (19)
- Brissos S, "The role of long-acting injectable antipsychotics in schizophrenia : a critical appraisal", Ther Adv Psychopharmacol, 4, pp.198~219 (2014)
- Pae CU, "Comparison between long-acting injectable aripiprazole versus paliperidone palmitate in the treatment of schizophrenia : systematic review and indirect treatment comparison", Int Clin Psychopharmacol, 32, pp.235~248 (2017)
- Wang SM, "Schizophrenia relapse and the clinical usefulness of oncemonthly aripiprazole depot injection", Neuropsychiatr Dis Treat, 10, pp.1605~1611 (2014)
- Otsuka Pharmaceutical Co., Ltd, "The manual of Abilify Maintena Kit" (2013), Otsuka Pharmaceutical Co., Ltd
- Changsu Han, "The Potential Utility of Aripiprazole Augmentation for Major Depressive Disorder with Mixed Features Specifier: A Retrospective Study", Clinical Psychopharmacology and Neuroscience, 17(4), pp.495~502 (2019), 대한정신약물학회[DOI]
- Jeong Ha Park, "Effects of Amisulpride Adjunctive Therapy on Working Memory and Brain Metabolism in the Frontal Cortex of Patients with Schizophrenia: A Preliminary Positron Emission Tomography", Computerized Tomography Investigation, 2019, pp.17(2), 250~260[DOI]
- Fleischhacker WW, "Aripiprazole once-monthly for treatment of schizophrenia : double-blind, randomised, noninferiority study", Br J Psychiatry, 205, pp.135~144 (2014)
- Kane JM, "Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia : a 52-week, multicenter, randomized, double-blind, placebo-controlled study", J Clin Psychiatry, 73, pp.617~624 (2012)
- Ishigooka J, "Efficacy and safety of aripiprazole once-monthly in Asian patients with schizophrenia : a multicenter, randomized, double-blind, non-inferiority study versus oral aripiprazole", Schizophr Res, 161, pp.421~428 (2015)
- Potkin SG, "Safety and tolerability of once monthly aripiprazole treatment initiation in adults with schizophrenia stabilized on selected atypical oral antipsychotics other than aripiprazole", Curr Med Res Opin, 29, pp.1241~1251 (2013)
- Kane JM, "Aripiprazole once-monthly in the acute treatment of schizophrenia : findings from a 12-week, randomized, double-blind, placebo-controlled study", J Clin Psychiatry, 75, pp.1254~1260 (2014)
- Fleischhacker WW, "Long-term safety and tolerability of aripiprazole once-monthly in maintenance treatment of patients with schizophrenia", Int Clin Psychopharmacol, 28, pp.171~176 (2013)
- Kane JM, "Hospitalisation rates in patients switched from oral anti-psychotics to aripiprazole once-monthly for the management of schizophrenia", J Med Econ, 16, pp.917~925 (2013)
- Schreiner A, "Switching from oral atypical antipsychotic monotherapy to paliperidone palmitate once-monthly in non-acute patients with schizophrenia: a prospective, open-label, interventional study", Psychopharmacology(Berl), 234, pp.3~13 (2017)
- Fleischhacker WW, "Critical review of antipsychotic polypharmacy in the treatment of schizophrenia", Int J Neuropsychopharmacol, 17, pp.1083~1093 (2014)
- Nielsen J, "10-year trends in the treatment and outcomes of patients with first-episode schizophrenia", Acta Psychiatr Scand, 122, pp.356~366 (2010)
- Gilmer TP, "Antipsychotic polypharmacy trends among Medicaid beneficiaries with schizophrenia in San Diego County, 1999-2004", Psychiatr Serv, 58, pp.1007~1010 (2007)
- Rabinowitz J, "To what extent do the PANSS and CGI-S overlap?", J Clin Psychopharmacol, 26, pp.303~307 (2006)
- Leucht S, "Linking the PANSS, BPRS, and CGI : clinical implications", Neuropsychopharmacology, 31, pp.2318~2325 (2006)